mrc
common
cold
unit
coomb
road
solisbuti
wilchir
uk
interferon
potenti
prophylact
agent
common
cold
problem
present
level
sideeffect
observ
nt
justifi
use
long
term
lobert
phillpott
describ
mechan
interferon
action
futur
hope
develop
use
prevent
cold
interferon
appear
ideal
antivir
drug
use
prevent
cold
extrem
potent
activ
wide
rang
virus
howev
toxic
system
use
minor
respiratori
ill
taken
adequ
dose
intranasahi
caus
mild
inflamm
mucosa
current
research
direct
toward
overcom
problem
peopl
common
cold
mild
selflimit
ill
howev
high
incid
cold
abil
caus
exacerb
chronic
underli
respiratori
diseas
lead
consider
morbid
research
establish
serologicaili
distinct
virus
caus
cold
littl
hope
infectica
control
vaccin
therefor
control
mean
broadspectrmn
antiviz
agent
ration
approach
interferon
without
doubt
potet
broadli
activ
antivir
agent
yet
discov
c
cours
limit
upon
knd
medic
could
use
prevent
cold
exampl
cheap
easi
manufactur
well
highli
effect
virtual
free
sideeffect
interferen
human
interferon
hulfn
pro
tein
glycoprotein
princip
type
hulfn
p
produc
cel
exposur
viru
wn
leucocyt
lfn
fibroblast
hulfn
also
produc
fibroblast
expos
doublestrand
rna
ifn
produc
lymphocyt
respons
antigen
mitogen
stimulu
interferon
directli
inhibit
viru
growth
exposur
mittfect
cell
interferon
make
resist
attack
virus
interferon
intern
cell
bind
cell
surfac
receptor
one
receptor
ifn
anoth
receptor
ifn
trigger
seri
event
within
cell
multipl
effect
observ
cell
includ
inhibit
penetr
matur
certain
virus
howev
princip
effect
interferon
treatrnent
seem
inhibit
viral
protein
synthesi
system
interferoninduc
enzym
describ
activ
doublestrand
rna
molecul
produc
replic
rna
druse
effect
enzym
inhibit
initi
viral
protein
synthesi
increas
rate
viral
mrna
degrad
within
cell
see
fig
futur
research
mldoubtedli
disclos
mechan
viru
growth
prevent
alreadi
evid
suggest
fn
differ
mechan
ktion
ifn
combin
ifn
ifn
ct
ifn
ifn
ifn
exhibit
synergi
potenc
variou
interferon
prepar
may
therefor
compar
term
unit
antivir
activ
speci
specif
process
v
absolut
mean
practic
human
interferon
must
use
treat
human
cell
human
interferon
may
produc
cell
cultur
vitro
partial
purifi
human
leucocyt
interferon
produc
finnish
red
cross
huffi
coat
cell
deriv
blood
donat
stimul
sendal
viru
howev
procedur
expens
amount
interferon
produc
limit
avail
buffi
coat
cell
recent
dna
copi
mrna
code
type
hulfn
synthes
insert
plasmid
vector
downstream
suitabl
prokaryot
promot
plasmi
introduc
bacteria
transfect
multipli
high
level
express
interferon
gene
sequenc
cheap
cost
undoubtedli
reduc
intranas
interferon
prevent
cold
initi
experi
common
cold
unit
wiltshir
uk
intranas
administr
partial
purifi
human
leucocyt
interferon
volunt
shown
prevent
cold
caus
rhinoviru
type
ref
rhinovirus
caus
approxim
cold
howev
leucocyt
donat
blood
requir
produc
mu
interferon
use
treat
volunt
furthermor
use
partial
purifi
materi
protein
interferon
also
rais
question
whether
interferon
respons
prevent
rhinoviru
infect
could
activ
due
contamin
biolog
activ
molecul
also
deriv
human
leucocyt
question
answer
experi
carri
hulfn
purifi
virtual
homogen
monoclon
antibodi
affin
column
shown
prevent
cold
caus
anoth
rhinoviru
type
ref
total
dose
mu
given
intranas
volunt
period
day
dose
dose
daili
four
dose
given
vixu
challeng
dramat
reduct
frequenc
cold
interferon
treat
group
tabl
accompani
lesser
reduct
number
volunt
shed
viru
increas
serum
neutral
antibodi
challeng
viru
experi
conduct
ident
protocol
close
similar
result
achiev
use
highli
purifi
hulfn
produc
escherichia
coil
manufactur
schere
plough
experi
clearli
demonstr
interferon
produc
bacteria
recombin
dna
techniqu
could
activ
produc
human
celk
interferon
use
prmtke
experi
interferon
given
intranas
larg
dose
physidan
therefor
ffinterferon
find
applic
prophylact
common
cold
two
question
answer
firstli
could
peopl
treat
interferon
use
simpl
design
nasal
spray
sccondli
minimum
quantiti
interferon
necessari
protect
infect
cold
virus
answer
question
sought
doserang
studi
volunt
gave
variou
dose
hulfn
use
fingeractu
nasal
spray
interferon
given
one
day
day
challeng
virul
human
rhinovirus
dose
interferon
vari
also
time
viru
challeng
relat
dose
period
maximum
vulner
viru
infect
could
identifi
result
studi
suggest
least
mu
ifn
selfadminist
intranas
time
daili
necessari
protect
experiment
rhinoru
infect
subsequ
experi
shown
mu
huifn
aa
similar
molecul
hulfn
produc
roch
protect
experiment
infecton
human
respnratori
coronavtru
see
fig
coronavirus
econd
frequent
encouat
caus
loid
respons
case
howev
one
requir
must
met
prophylact
common
cold
almost
complet
freedom
unpleas
sndeeffect
research
run
difficulti
studi
shown
regimen
ifn
similar
propos
seem
necessa
protect
natur
cold
dose
also
toxi
produc
mild
inflamm
nasal
mucosa
recent
stuli
univers
virginia
prclorg
intranas
administr
hulf
associ
muxrd
irrit
ot
recipi
l
histolog
mark
epitheli
acut
qfiammat
ulcer
occurr
pronounc
submucos
lanphoq
tic
mononuclear
cell
filtrat
although
abnorm
resolv
within
week
stop
treatment
longterm
administr
ifn
would
accept
howev
littl
sign
irrit
volum
wen
interferon
fr
day
therefor
interferon
prophylaxi
could
use
time
exposur
viru
fear
exposur
viru
predict
exampl
situat
would
contact
cold
suffer
examin
import
event
ever
reason
believ
problem
poor
toler
intranas
interferon
overcom
small
number
interferon
test
antivir
activ
toxic
nose
conceiv
molecular
subspeci
hulfn
c
huifn
hulfn
hybrid
interferon
molecul
prepar
may
improv
therapeut
ratio
interferon
could
taken
prolong
period
prophylact
common
cold
patient
underli
chronic
respiratori
diseas
bronchiti
asthma
surprisingli
therefor
discoveri
inteffemn
desir
properti
one
major
goal
common
cold
research
today
question
whether
interferon
use
treat
cold
also
remain
open
rel
short
cours
ill
suggest
viru
replic
nose
oomn
rapidli
may
even
essenti
complet
time
symptom
begun
howev
pessimist
view
yet
confirm
evid
suggest
even
rel
wek
antivir
agent
enviroxim
regist
trade
name
produc
eli
lilli
compani
administ
local
viru
infect
affect
cours
cold
tt
perhap
suitabl
prepar
interferon
could
time
potent
enviroxim
vitro
could
prove
clinic
use
modul
appetit
intiuen
neurotransmitt
physicochem
properti
food
therefor
receiv
less
promin
outset
stresd
complex
appetit
regul
make
extrem
unlik
singl
agent
prove
holi
grail
appetit
suppress
futur
pharmacolog
approach
need
take
cogniz
fact
attempt
tailor
treatment
individu
rather
individu
treatment
particularli
import
view
fact
major
peptid
appear
multipl
effect
make
like
indiscrimin
use
agent
subject
deficit
excess
demonstr
lead
unaccept
high
incid
side
effect
opuad
read
larg
bodi
evid
accumul
support
role
opioid
peptid
modul
feed
behavior
particular
rel
specif
opioid
antagonist
naloxon
demonstr
decreas
fede
varieti
condit
mani
speci
includ
human
human
howev
major
effect
opioid
blockad
naloxon
appear
reduc
carbohydr
intak
rather
produc
absolut
reduct
calori
reduct
offset
increas
fat
intak
addit
first
ion
term
studi
human
atkinson
use
longact
opiat
antagonist
naltrexon
produc
disap
